Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR)
CUSIP: 929033207
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 43,408,727
- Total 13F shares
- 3,710,338
- Share change
- +3,648,963
- Total reported value
- $180,767,786
- Put/Call ratio
- 20%
- Price per share
- $48.72
- Number of holders
- 35
- Value change
- +$180,382,226
- Number of buys
- 34
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 929033207?
CUSIP 929033207 identifies VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2025
Recent filing periods for CUSIP 929033207:
Top shareholders of VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
61%
|
39,646,039
|
$64,226,583 | — | 30 Jun 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
9.8%
|
6,361,723
|
$10,305,991 | — | 30 Jun 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
1.7%
|
2,092,686
|
$5,231,715 | -$10,824,525 | 30 Jun 2025 | |
| 5AM Ventures VI, L.P. |
13D/G
3/4/5
|
Andrew J. Schwab · 10%+ Owner |
3.5%
|
4,422,863
|
$4,422,863 | $0 | 08 Jul 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3%
|
1,915,606
|
$3,103,282 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
2.4%
|
1,531,636
|
$2,481,250 | — | 30 Jun 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
1.7%
|
1,074,658
|
$1,139,137 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.81%
|
525,613
|
$851,493 | — | 30 Jun 2025 | |
| Sarissa Capital Management LP |
13F
|
Company |
0.78%
|
508,016
|
$822,986 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.73%
|
474,575
|
$768,000 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.72%
|
468,112
|
$758,341 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.67%
|
435,560
|
$705,768 | — | 30 Jun 2025 | |
| Scientech Research LLC |
13F
|
Company |
0.62%
|
403,859
|
$654,252 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.58%
|
374,763
|
$607,116 | — | 30 Jun 2025 | |
| Robert Ang |
3/4/5
|
PRESIDENT AND CEO, Director |
—
mixed-class rows
|
1,736,318
mixed-class rows
|
$510,338 | — | 06 May 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.43%
|
275,912
|
$447,000 | — | 30 Jun 2025 | |
| Nathan D. Jorgensen |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
289,403
mixed-class rows
|
$331,455 | — | 06 May 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.28%
|
180,788
|
$292,877 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.26%
|
169,636
|
$274,810 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.18%
|
115,934
|
$187,813 | — | 30 Jun 2025 | |
| Eyal C. Attar |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
441,625
mixed-class rows
|
$179,808 | — | 13 Feb 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.15%
|
94,394
|
$152,918 | — | 30 Jun 2025 | |
| Trustees of Columbia University in the City of New York |
13F
|
Company |
0.14%
|
91,910
|
$148,894 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.13%
|
87,485
|
$141,726 | — | 30 Jun 2025 | |
| Tirtha Chakraborty |
3/4/5
|
Chief Sci Off & Head Tech Ops |
—
mixed-class rows
|
532,416
mixed-class rows
|
$121,752 | — | 06 May 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.11%
|
72,417
|
$117,316 | — | 30 Jun 2025 | |
| Bollard Group LLC |
13F
|
Company |
0.09%
|
55,555
|
$90,000 | — | 30 Jun 2025 | |
| DGS Capital Management, LLC |
13F
|
Company |
0.13%
|
55,300
|
$89,586 | — | 30 Jun 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.06%
|
40,943
|
$66,328 | — | 30 Jun 2025 | |
| Amy Quinlan |
3/4/5
|
Vice President of Finance |
—
class O/S missing
|
50,312
|
$43,268 | — | 06 Nov 2024 | |
| Han Wook Choi |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
366,280
mixed-class rows
|
$33,844 | — | 01 May 2025 | |
| Chicago Partners Investment Group LLC |
13F
|
Company |
0.02%
|
10,887
|
$22,754 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
8,997
|
$14,575 | — | 30 Jun 2025 | |
| MAI Capital Management |
13F
|
Company |
0.01%
|
3,652
|
$5,917 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
2,295
|
$3,718 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
1,017
|
$1,648 | — | 30 Jun 2025 | |
| NBC SECURITIES, INC. |
13F
|
Company |
0%
|
1,000
|
$1,000 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
610
|
$989 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
503
|
$815 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
400
|
$648 | — | 30 Jun 2025 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
60
|
$98 | — | 30 Jun 2025 | |
| Christopher Slapak |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
116,000
|
— | — | 01 Feb 2022 | |
| Alexander Cumbo |
3/4/5
|
Director |
—
class O/S missing
|
60,000
|
— | — | 16 Jul 2025 | |
| Michel Detheux |
3/4/5
|
Director |
—
class O/S missing
|
60,000
|
— | — | 16 Jul 2025 | |
| Sarah Burgess Reed |
3/4/5
|
Director |
—
class O/S missing
|
60,000
|
— | — | 08 Sep 2025 | |
| Daniella Beckman |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 22 May 2025 | |
| David Charles Lubner |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 22 May 2025 | |
| Erez Kalir |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 22 May 2025 | |
| Fouad Namouni |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 22 May 2025 | |
| Joshua Resnick |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 22 May 2025 |
Institutional Holders of Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q4 2025 Across Filers
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.